Description

Drug Classification:

Ibandronate acid belongs to the bisphosphonate class of medications. It acts as a potent inhibitor of bone resorption and is primarily used in the management of osteoporosis and other bone-related disorders.

Formulations:

• Ibandronate Acid Tablets:
  • Strength: Available in 150mg formulations.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 1 tablet each, ensuring precise dosing and ease of use.
• Ibandronate Acid Liquid Ampules:
  • Strength: Available in 3mg formulations.
  • Product Form: Liquid ampules for parenteral administration.
  • Packing Specifications: Packaged individually to maintain product integrity and sterility.

Indications:

Ibandronate Acid Tablets and Ampules are indicated for the treatment and prevention of osteoporosis in postmenopausal women and men at risk of fractures. They are also used to increase bone mass in patients with glucocorticoid-induced osteoporosis.

Usage:

• Tablets:
  • Ibandronate Acid Tablets should be taken orally, preferably in the morning on an empty stomach.
  • Patients should swallow the tablet whole with a full glass of plain water (not mineral water) while sitting or standing upright to prevent esophageal irritation.
  • Avoid lying down for at least 60 minutes after taking the tablet to minimize the risk of esophageal adverse effects.
• Ampules:
  • Ibandronate Acid Liquid Ampules are administered via intravenous infusion over a period of time determined by healthcare professionals.

Dosage:

• The recommended dosage of Ibandronate Acid varies based on the indication and formulation.
• For the treatment of osteoporosis, the usual dose is one 150mg tablet once monthly or one 3mg ampule once every three months.
• Adequate intake of calcium and vitamin D is important during treatment to support bone health and minimize the risk of hypocalcemia.

Pharmacokinetics:

• Ibandronate acid is poorly absorbed from the gastrointestinal tract, with an estimated oral bioavailability of less than 1%.
• Peak plasma concentrations are achieved within 0.5 to 2 hours after oral administration, with a terminal half-life of approximately 10 hours.

Pharmacodynamics:

• Ibandronate acid inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, thereby preventing their dissolution and reducing bone turnover.
• This leads to an increase in bone mineral density and a decrease in the risk of fractures, making it an essential therapy for osteoporosis management.

Side Effects:

• Common side effects of Ibandronate Acid Tablets and Ampules may include gastrointestinal disturbances such as abdominal pain, nausea, and dyspepsia.
• Rare but serious adverse effects may include osteonecrosis of the jaw, atypical femoral fractures, and esophageal irritation.
• It is important to discuss any persistent or severe side effects with your healthcare provider.

Trust in the effectiveness and reliability of Ibandronate Acid Tablets and Ampules from AIT Pharmaceuticals Division. We are committed to providing high-quality medications to support your bone health needs. For more information, please visit our website or consult your healthcare provider.